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PHOX2B and its paralogue gene PHOX2A are two homeodomain proteins in the network regulating the
development of autonomic ganglia that have been associated with the pathogenesis of neuroblastoma
(NB), because of their over-expression in different NB cell lines and tumour samples. We used the SK-N-
BE(2)C cell line to show that all-trans retinoic acid (ATRA), a drug that is widely used to inhibit growth
and induce differentiation in NBs, regulates both PHOX2A and PHOX2B expression, albeit by means of
different mechanisms: it up-regulates PHOX2A and down-regulates PHOX2B. Both mechanisms act at
transcriptional level, but prolonged ATRA treatment selectively degrades the PHOX2A protein, whereas
the corresponding mRNA remains up-regulated. Further, we show that PHOX2A is capable of modulating
PHOX2B expression, but this mechanism is not involved in the PHOX2B down-regulation induced by
retinoic acid. Our ﬁndings demonstrate that PHOX2A expression is ﬁnely controlled during retinoic acid
differentiation and this, together with PHOX2B down-regulation, reinforces the idea that they may be
useful biomarkers for NB staging, prognosis and treatment decision making.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
A neuroblastoma, one of the most frequent tumours of child-
hood, is caused by the arrested differentiation of neural crest
sympatho-adrenal progenitor cells [1]. PHOX2B, and its paralogue
PHOX2A, are two homeodomain transcription factors that play a
pivotal role in the development of the autonomic nervous system
and speciﬁcation of the neurotransmitter phenotype by control-
ling the expression of the two enzymes responsible for nora-
drenaline biosynthesis (tyrosine hydroxylase [TH] and dopamine-
β-hydroxylase [DβH]), and thus directing neurons towards theirr Inc. This is an open access article
choline Receptor; ATRA, all-
tein-2; CCHS, Congenital
dent kinase; ChIP, chromatin
ine-β-hydroxylase; DR, di-
r; HSCR, Hirschprung's dis-
retinoic acid receptor; RARE,
eptor; TH, tyrosine hydro-
myelocytomatosis viral
itute, Via Vanvitelli 32, 20129terminal noradrenergic differentiation [2,3]. PHOX2B also mod-
ulates its own expression by means of an auto-regulatory me-
chanism [4] and the expression of PHOX2A [5,6], whereas PHOX2A
regulates the expression of the human α3 nAChR subunit gene [7].
Both therefore play a primary role in controlling a number of the
molecular determinants of autonomic neurons.
PHOX2A and PHOX2B are also involved in coordinating cell
cycle exit and the differentiation of neural progenitors during
sympathetic neuronal differentiation [8] as a result of their ability
to induce the transcription of p27Kip1 [9–11], a cyclin-dependent
kinase inhibitor (CKI) whose expression is also regulated by re-
tinoic acid (RA) at post-translational level [12], followed by
PHOX2B down-regulation during ﬁnal neuronal differentiation
[13].
Recently, the PHOX2A gene has been localised to near the de-
letion breakpoint of a number of 11q-deleted NB specimens [14],
and microarray expression analysis has shown that it is one of nine
noradrenaline biosynthesis pathway genes whose expression is
reduced in unfavourable NB tumours [14]. However, the possible
contribution of PHOX2A to the pathogenesis of NB is not univocal
as it is over-expressed in a number of NB tumours and cell lines
[15]. As no mutations have been observed in the PHOX2A reg-
ulatory or coding regions of tumour samples [14,16], it is likely
that this gene is involved in the pathogenesis of NB when itsunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The pathogenetic role of PHOX2B in NB is supported by the
presence of heterozygous mutations in familial, sporadic and
syndromic cases of NB, and its over-expression in tumour samples
and NB cell lines, sometimes associated with other neurochristo-
pathies such as Congenital Central Hypoventilation Syndrome
(CCHS) and Hirschprung's disease (HSCR) [16–23], but the under-
lying mechanisms are still largely unknown. In vitro and in vivo
studies have linked the PHOX2B mutations associated with NB
with the impaired differentiation of immature sympathetic neu-
rons that can proliferate, and aberrant differentiation towards the
glial lineage [10,24]. PHOX2B over-expression leads to contra-
dictory results as some studies indicate that it inhibits the pro-
liferation of motoneuron progenitors and of immature sympa-
thetic neurons [8,10,16] and promotes the differentiation of hu-
man NB cells after treatment with RA [16], whereas conditional
Phox2b knockout studies have revealed that Phox2b is required for
the proliferation of immature sympathetic neurons [25], and Alam
et al. [13], and Ke et al. [23] have shown that a high level of
PHOX2B promotes neuroblastoma cell proliferation and xenograft
tumour growth in the TH-MYCN murine model, and that this
correlates with a high level of MYCN expression. Furthermore, the
presence of aberrant Phox2b expression in a zebraﬁsh model has
shown that the correct amount of the Phox2b gene is important for
the differentiation of sympathetic neurons [26].
Vitamin A (retinol) profoundly affects various biological pro-
cesses during development and adulthood. Most of its actions are
mediated by its metabolic product, retinoic acid, which binds to
speciﬁc nuclear receptors: heterodimers of retinoic acid receptors
(RARs) α, β and γ, and retinoid X receptors (RXRs) α, β and γ. These
ligand-activated receptors regulate gene transcription by binding
to retinoic acid responsive elements (RAREs) in the promoter re-
gions of responsive genes [27]. At embryological level, retinoids
control the proliferation, migration and differentiation of neural
crest-derived progenitors and, in developing sympathetic neurons,
RA cooperates with Bone morphogenetic protein-2 (BMP-2) to
make cells responsive to neurotrophic factors such as glial derived
neurotrophic factor (GDNF) and neurotrophin 3 (NT3) [28,29]. The
pleiotropic effects of RA on the regulatory network governing
sympathetic neuron differentiation are well known, but very little
is known about its effect on the transcription factors (such as
MASH1, PHOX2A and PHOX2B) that play a fundamental role in this
process. In vitro, retinoids arrest cell growth in the G1 phase of the
cell cycle, and induce differentiation in human NB cell lines [30,31]
along neuronal- or glial-like lineages depending on the cell line
[32] by regulating, for example, the expression of p27Kip1, a target
gene of PHOX2A and PHOX2B that has major functions in con-
trolling the cell cycle.
As the target genes mediating retinoid-induced differentiation
are largely unknown, and the molecular mechanisms by which RA
regulates the different signalling pathways necessary for retinoid-
induced cellular differentiation in various tissues and at different
times are poorly understood, we tested the hypothesis that there
may be a direct regulatory link between RA and PHOX2A and
PHOX2B expression/activity in the SK-N-BE(2)C NB cell line. The
ﬁndings show that the retinoic-acid induced differentiation of SK-
N-BE(2)C cells is accompanied by a differential regulation of
PHOX2A and PHOX2B expression, with up-regulation of PHOX2A
mRNA followed by the disappearance of PHOX2A protein (the
mRNA remains stably expressed), and a marked decrease in the
expression of PHOX2B mRNA and protein, thus suggesting that
their expression must be ﬁnely controlled during RA-induced
differentiation, reinforcing the idea that they may be useful bio-
markers for NB staging, prognosis and treatment decision making.2. Material and methods
2.1. Cell lines and cultures
The SK-N-BE(2)C and IMR32 human neuroblastoma cell lines
were grown in RPMI 1640, 10% fetal calf serum, 100 units/ml pe-
nicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine (Lonza).
All-trans retinoic acid (ATRA; Sigma-Aldrich, St.Louis, Missouri,
USA), dissolved in 100% EtOH, was added at a ﬁnal concentration
of 10 μM for the times described in the and the medium was
changed every day. Each treatment was carried out in duplicate
and repeated at least three times in independent experiments
using different batches of ATRA. Cycloheximide (Sigma-Aldrich, St.
Louis, MO, USA) was added at a ﬁnal concentration of 10 μg/ml
before or after ATRA for the times described in the The proteasome
inhibitor MG-132 (8 μM; Calbiochem, Darmstadt, Germany) was
added for eight and 24 h after initial treatment with ATRA for 24
and 48 h.
2.2. Total RNA extraction, reverse transcription, and quantitative
real-time PCR
Total RNA was extracted and reverse transcribed, and gene ex-
pression was quantitatively analysed as described by Benfante et al.
[33] with minimal modiﬁcations. The TaqMan
s
primer and probe as-
says (Life Technologies, Inc., Carlsbad, CA, USA) were PHOX2A (ID
#Hs00605931_mH) and PHOX2B (ID #Hs00243679_m1), and glycer-
aldehyde-3-phosphate dehydrogenase (GADPH; ID# Hs99999905_m1)
was used as an endogenous controls after its compatible with the
other assays had been conﬁrmed. The results were calculated using
the 2ΔCT and the 2ΔΔCT methods in order to allow the normal-
isation of each sample to the endogenous control, and comparison
with the calibrator of each experiment (set to a value of 1) as described
in the ﬁgure legends.
2.3. Nuclear run-on
Nuclear run-on transcription was performed in accordance
with the protocol described by Patrone et al. [34]. The nuclei
(5107) were prepared from SK-N-BE(2)C cells treated for 24 h
with ATRA or vehicle. RNA was synthesised in vitro by adding an
equal volume of transcription buffer containing 0.4 mM biotin-16-
UTP (Roche Diagnostics SpA, Monza, Milan, Italy), and the biotin-
labelled RNA was isolated by means of streptavidin-coated mag-
netic beads (Dynabeads M-280 Streptavidin, Dynal Biotech ASA,
Oslo, Norway). Gene expression was quantitatively analysed by
reverse transcribing 8 ml of the nuclear RNA sample and 1 mg of the
total RNA sample and using real-time PCR.
2.4. Chromatin immunoprecipitation and qPCR
Chromatin immunoprecipitation was carried out as previously
described [4]. Chromatin was incubated overnight at 4 °C with
5 mg of anti-PHOX2A antibody (Davids Biotechnologie, Regensburg,
Germany), and chicken pre-immune IgY (Davids Biotechnologie),
and the immunocomplexes were collected on monoclonal anti-
chicken IgY-agarose beads or protein G/agarose bead slurry (In-
Vitrogen, Carlsbad, CA, USA) pre-adsorbed with 20 mg/ml tRNA and
10 mg/ml salmon sperm DNA (Sigma-Aldrich). After washes and
elution, the cross-linking was reversed by heating to 65 °C over-
night, and the samples were puriﬁed on columns (High Pure PCR
product puriﬁcation kit, Roche Diagnostics SpA, Italy). For the PCR
detection of the immunoprecipitated chromatin, 5% of the puriﬁed
DNA was used as a template to amplify the PHOX2B promoter
using the primers ChIP[2 bprom] UP, 5′-CAA GCT TAT TTC CAA GTA
GTG TGA TTG AAT-3′, and ChIP[2bprom] LOW, 5′-GCC TCC TAT
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95 °C for 2 min, followed by 47 cycles of heating at 95 °C for 30 s,
annealing at 64 °C for 30 s, and extension at 72 °C for 30 s. For
quantitative analysis, the immunoprecipitated chromatin was
ampliﬁed by means of SYBR-Green chemistry (Life Technologies,
Inc.) using the primers #UP, 5′-GCT CGG TGC GTA ATG GTG TGG
TA-3′ and #LOW, 5′-GGT TGG TCT TAT TGC TGG CGC TT-3′, and
quantitatively analysed using the ABI Prism™ 7000 Sequence
Detection System (Applied Biosystems, CA, USA) and SDS software,
version 1.2.3.
2.5. shRNA
PHOX2A expression was silenced by means of the transient
transfection of a plasmid (MISSIONs shRNA, Cod. SHCLNG-
NM_005169, TRCN0000013543, Clone ID:NM_005169.2-
1260s1c1) containing an shRNA targeting the 3′-UTR region of
PHOX2A (Sequence: CCG GCC TTC TAG CTT GGC CTT CTT TCT CGA
GAA AGA AGG CCA AGC TAG AAG GTT TTT) and the results were
analysed as described in the SHC002 MISSIONs pLKO.1-puro Non-
Mammalian shRNA Control Plasmid DNA (Sigma-Aldrich) was
used as the control.
2.6. Electrophoretic mobility shift assays (EMSAs)
The EMSAs were performed as described by Terzano et al. [35]
and Cargnin et al. [4]. The oligonucleotides spanning the ATTA
sites in the PHOX2B promoter have been described by Cargnin
et al. [4] and all of the oligonucleotides were purchased from
Sigma Aldrich.
2.7. Plasmid construction
The β-RARE luc construct was obtained by cloning the con-
sensus RARE from the β2 RA receptor subunit promoter [36] up-
stream of the SV40 promoter (Promega Madison, WI, USA). The
oligonucleotide sequence was 5′-TCG AGT AAG GGT TCA CCG AAA
GTT CAC TCG CAC-3′, in which the RARE sequence is underlined.
Some of the reporter constructs containing regions of the
PHOX2A promoter have been previously described by Flora et al.
[5]. However, as these regions were cloned into the pGL3basic
vector backbone and this was unspeciﬁcally transactivated by
ATRA treatment, we re-cloned fragments of the human PHOX2A 5′-
ﬂanking region into the ATRA-unresponsive pGL4basic plasmid
(Promega) upstream of the Fireﬂy luciferase gene. Details con-
cerning the plasmid construction are available in the Supplemen-
tary Material. The PHOX2A expression vector was obtained by
cloning human PHOX2A cDNA [7] into the EcoRI site of pCMV-myc
(Clontech Laboratories Inc., Mountain View, CA, USA). All of the
constructs were checked by means of restriction analysis and
partial sequencing.
2.8. Transfections and luciferase assays
The transfection experiments were performed by means of li-
pofection as described by Flora et al. [37] using 1.6105 SK-N-BE
(2)C cells. Luciferase was assayed using the Dual Luciferase Re-
porter Assay System as previously described [5,38].
2.9. Protein preparation, immunoprecipitation and western blot
analysis
The total protein extracts were obtained from sub-conﬂuent
cells using the freeze and thaw method as described by Benfante
et al. [33] and the nuclear extracts were prepared as previously
described [35].For immunoprecipitation, SK-N-BE(2)C cells were harvested
after being treated with ATRA and MG-132 as described in the by
means of centrifugation at 7000 rpm for 5 min. The pellet was
resuspended in 150 ml lysis buffer containing non-ionic detergent
(1% Triton X-100, 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 2 mM
EDTA, 0.5 mM DTT, 0.2 mM PMSF, and the Sigma-Aldrich protease
inhibitors cocktail), and incubated for one hour at 4 °C on a ro-
tating wheel. The extracts were then clariﬁed by means of 30 min
centrifugation at 13,200 rpm/4 °C, and pre-cleared using protein
G/agarose bead slurry (InVitrogen) and chicken pre-immune IgY
(Santa Cruz Biotechnology, Inc., Dallas, Texas, USA). Three milli-
grams of the pre-cleared extracts were incubated overnight at 4 °C
with 5 μg polyclonal chicken anti-PHOX2A antibody (Davids Bio-
technologie), or pre-immune chicken IgY (Santa Cruz Biotechnol-
ogy) and the immunocomplexes were captured by protein G/
agarose bead slurry (InVitrogen). Because of the poor binding of
chicken antibodies to protein G, a bridging antibody (rabbit anti-
chicken IgG, Upstate, Lake Placid, NY, USA) was added to enhance
the capture of the immunocomplexes. The beads were collected by
means of centrifugation, gently washed, and resuspended in
sample loading buffer, and the immunocomplexes were dis-
sociated from the beads by boiling the samples.
The proteins were separated by means of 10% SDS-PAGE and
transferred to a nitrocellulose membrane (Schleicher & Schuell
BioScience GmbH, Dassel, Germany), and Western blotting was
carried out as previously described [7] using the chicken anti-
PHOX2A [7], mouse monoclonal anti-PHOX2B (B-11), rabbit anti-
Sp1 (Santa Cruz Biotechnology), mouse anti-β-tubulin (Sigma-Al-
drich) and mouse anti-Ubiquitin (BIOMOL GmbH, Hamburg, Ger-
many) as primary antibodies; the secondary antibodies (rabbit
anti-chicken, Davids Biotechnologie; goat anti-rabbit and anti-
mouse, Pierce Biotechnology Inc., Rockford, ME, USA) were con-
jugated with horseradish peroxidase. The bands were revealed
using Super Signal West Dura (Pierce Biotechnology Inc.), with
standard molecular weights (New England Biolabs Inc., Beverly,
MA USA) being loaded in parallel.
2.10. Data analysis
NIH Image 1.61/fat software was used for the densitometric
analysis of the signals obtained from the Western blots. The results
are given as the mean values of at least three independent ex-
periments, and standard deviation (SD) or standard error (SEM) as
indicated in the The data were analysed by means of a paired two-
tailed Student's t test or one-way ANOVA using GraphPad Prism
5 Software (GraphPad Software, Inc.) as described in the; p values
of o0.05 were considered signiﬁcant.3. Results
3.1. Effects of ATRA on PHOX2A and PHOX2B expression
The effect of ATRA on the expression of PHOX2A and PHOX2B
was studied using the SK-N-BE(2)C NB cell line, a very well-char-
acterised model of RA-induced neuronal differentiation [39]. Its
differentiation potential was tested by treating the cells with
10 μM ATRA for different periods of time, evaluating their mor-
phology and the differential expression of some target genes, and
measuring the responsiveness of a reporter construct in which
transcription was driven by the RARE. Phase-contrast microscopy
showed that the morphology of the SK-N-BE(2)C cells started
changing after 24 h of ATRA exposure (Fig. S1A, panel b), and
neurite outgrowth was clearly evident after 72 h (Fig. S1A, panel
c); exposure to the vehicle alone did not affect their morphology at
any time (Fig. S1A, panels d and e), leaving them indistinguishable
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At molecular level, ATRA-induced SK-N-BE(2)C cells differ-
entiation is characterised by changes in the expression of some
target genes, including HASH1 [40,41], and Northern blot analysis
of RNA from the cells treated with ATRA for different times re-
vealed a unique transcript of approximately 3 Kb encoding HASH1
(Fig. S1B, lanes 1, 2 and 4), which was observed in all of the tested
NB cells, whereas no signal was observed in the HeLa cells (Fig.
S1B, lane 3). After 24 h exposure to ATRA, the expression of the
transcript became barely detectable (Fig. S1B, lane 5) and re-
mained very low for up to 96 h (Fig. S1B, lanes 6–8). This is in line
with the ﬁndings of Söderholm et al. [41] and, together with the
morphological data, indicates that the most relevant biological
responses of neuroblastoma cells to ATRA exposure were com-
pletely reproducible under our experimental conditions.
The responsiveness of SK-N-BE(2)C cells to ATRA was also tes-
ted by means of the transient transfection of a reporter construct
in which the transcription was driven by the RARE identiﬁed in the
promoter of the β2 subunit of retinoic acid receptor (β-RARE luc),
cloned upstream of SV40 promoter. Fig. S1C shows that the SK-N-
BE(2)C cells were fully responsive to ATRA treatment as the ex-
pression of the luciferase reporter gene increased 40-fold over that
of untreated cells (compare lanes 1 and 2). Treatment with vehicle
alone had no effect on the luciferase (Fig. S1C, lane 3). All of these
data further conﬁrm that the most relevant biological responses of
SK-N-BE(2)C cells to ATRA exposure were completely reproducible
under our experimental conditions.
Fig. 1A shows that the PHOX2A transcript [5] was considerably
induced after 24 h exposure to ATRA, and this level of expression
increased for up to 72 h (Fig. 1A, hatched vs grey bars), whereas
exposure to the vehicle alone did not affect PHOX2A expression atFig. 1. Effects of ATRA on PHOX2A and PHOX2B expression in SK-N-BE(2)C cells. (A and B
cells were treated with ATRA for the indicated times, and gene expression was determin
represent the mean values7SD of three independent experiments expressed as fold-ind
empty (panel B) bars¼treated cells; grey bars¼vehicle-treated samples. **po0.01; an
mRNA expression between the vehicle treated (grey bars) and the cells treated with A
Western blots of total protein extracts obtained from SK-N-BE(2)C cells treated with ATRA
18 in panel C and 2, 4 and 6 in panel D) for different periods of time. The ﬁlter was
membranes were probed with an antibody against β-tubulin for normalisation purposes
and IMR32 cells (panel C, lane 20, and panel D, lane 8). Lanes 1 and 2 (panel C), and laany time (Fig. 1A, grey bars vs black bar). The induction of PHOX2A
mRNA by RA was reproducible and statistically signiﬁcant. On the
contrary, PHOX2B transcript expression decreased by 70% after 24 h
exposure, and by up to 90% after 72 h (Fig. 1B, white vs grey bars).
Western blot analysis was used to evaluate whether the in-
duction of PHOX2A mRNA and reduction in PHOX2B mRNA ex-
pression was paralleled by an adequate increase/decrease in the
corresponding protein. Fig. 1C shows that, after 24 h treatment
with ATRA, there was a substantial and statistically signiﬁcant
increase in PHOX2A protein levels (Fig. 1C, lanes 3 and 4 vs control
lanes 1 and 2); however, surprisingly, no trace of the protein was
found after 48 h and for up to 96 h (Fig. 1C, lanes 5–10). On the
contrary, PHOX2B protein was not detectable after no more than
24 h ATRA treatment (Fig. 1D, lanes 3, 5 and 7 vs lanes 2, 4 and 6).
3.2. ATRA acts at transcriptional level
We used nuclear run-on experiments to investigate whether
ATRA acts directly at transcriptional level. Fig. 2A and B (TOT RNA)
conﬁrmed that 24 h ATRA exposure induced a three-fold increase
in PHOX2A and three-fold decrease in PHOX2B mRNA expression,
and the quantitative run-on experiments showed that this changes
were due to the new induction or repression of transcription
caused by the drug (Fig. 2A and B, RUN-ON RNA). In brief, ATRA
increased PHOX2A and decreased PHOX2B mRNA levels by acting
on their transcription.
3.3. Mapping the retinoic acid responsive elements (RAREs)
The nuclear run-on analyses (Fig. 2) showed that the changes in
PHOX2A and PHOX2B relative expression was mainly due to a) qPCR analyses of PHOX2A (panel A) and PHOX2B expression (panel B). SK-N-BE(2)C
ed by means of real-time PCR using the GAPDH gene as an internal control. The bars
uction in comparison with the untreated sample (black bars). Hatched (panel A) and
d ***po0.001 indicate statistically signiﬁcant differences in PHOX2A and PHOX2B
TRA for different periods of time (one-way ANOVA, post-Tukey's test). (C and D)
10 μM (lanes 3–10 in panel C, and lanes 3, 5 and 7 in panel D) or ethanol (lanes 11–
probed with the anti-PHOX2A (panel C) or anti-PHOX2B antibody (panel D). The
. The negative and positive controls were protein extracts of HeLa (panel C, lane 19)
ne 1 (panel D): untreated cells.
Fig. 2. Effects of ATRA on the transcription of PHOX2A and PHOX2B mRNA. (A and B) Run-on analysis. The SK-N-BE(2)C cells were treated with ATRA for 24 h, and PHOX2A
(panel A) and PHOX2B gene expression (panel B) was determined by means of real-time PCR using the GAPDH gene as an internal control. The bars represent the mean
values7SD of three independent experiments using total and nuclear run-on RNA in the treated cells (striped bars), expressed as fold-induction over the vehicle-treated
samples (black bars). **po0.01 and ***po0.001 (one-way ANOVA, post-Tukey's test).
S. Di Lascio et al. / Experimental Cell Research 342 (2016) 62–7166transcriptional mechanism. A computer-assisted analysis of 10 Kb
of the PHOX2A promoter sequence using MatInspector software
(www.genomatix.de) revealed the presence of putative RAREs,
which may explain the increased PHOX2A expression induced in
the SK-N-BE(2)C cell line by ATRA treatment.
Ten putative RAREs were identiﬁed, two of which (#2 and #3)
partially overlapped. Most of the RAREs were directed repeats
separated by one nucleotide (DR1), two were DR2 (#6 and #8) and
only one was a DR5 (#7), although none of them perfectly mat-
ched the consensus (Fig. 3A). In order to test whether these sites
were functionally responsive to RA, we generated a series of
constructs spanning the PHOX2A promoter from position
10.53 Kb to position 0.35 Kb, and performed transient trans-
fections. The KpnI-NcoI fragment (Fig. 3B, 10.8/pGL4), which
contains all ten RAREs, and the SphI-NcoI fragment (Fig. 3B, 6.6/
pGL4), which contains RAREs 1–6, responded to ATRA treatment
with an almost ﬁve-fold induction of construct activity in com-
parison with the vehicle-treated cells. The SacI-NcoI fragment
(Fig. 3B, 4.5/pGL4), which spans 5.2 Kb of the promoter up-
stream of the transcriptional start site and contains RAREs 1–4,
was also responsive, although to a lesser extent (Fig. 3B). However,
further deletion of RARE 4 (construct 1.5/pGL4) did not affect the
activity of the PHOX2A promoter, which remained fully responsive
to ATRA. The 1.2/pGL4 construct containing only the RARE 1 se-
quence also remained responsive, and showed a statistically sig-
niﬁcant two-fold increase in promoter activity in comparison with
the vehicle-treated cells, whereas the deletion of RARE 1 (Fig. 3B,
0.35/pGL4) completely abolished the ability of ATRA to induce
PHOX2A promoter activity.
These data indicate that the responsiveness to ATRA is a result
of the contribution of the three RARE sequences located in the ﬁrst
1.5 Kb of the PHOX2A promoter.
On the other hand, in silico analysis of the PHOX2B promoter
did not reveal the presence of canonical RARE elements, thus
suggesting that the down-regulation of PHOX2B expression is not
mediated by the direct binding of RA receptors to the promoter,
and that other transcription factors mediate the effect of RA on
PHOX2B gene expression.
3.4. Down-regulation of PHOX2B expression is not due to a direct
effect of PHOX2A
Control of the temporal and spatial expression of PHOX2A and
PHOX2B is fundamental during the speciﬁcation of neuronalidentity, and many studies have tried to elucidate the exact mo-
lecular mechanisms involved in regulating their expression over
the last few years. We have previously demonstrated that PHOX2B
regulates the transcription of the PHOX2A gene by directly binding
and transactivating its promoter [5]. We have also characterised
the PHOX2B promoter, and demonstrated by means of biochemical
and functional assays that most of its transcriptional activity is
sustained by auto-regulatory mechanisms involving PHOX2B
binding and transactivation [4].
Chromatin immunoprecipitation (ChIP) assays show that
PHOX2A also participates in the transcriptional complex as-
sembled on the PHOX2B promoter [4] (Fig. 2S, panels A and B). The
PHOX2B promoter has ﬁve binding sites for homeodomain proteins
(Fig. S2D), and EMSA analysis (Fig. 2S, panel C) showed that
PHOX2A is also capable of binding the ATTA2 (Fig. 2S panel C, lanes
7–10) and ATTA3 (Fig. 2S panel C, lanes 12–15) sites in the PHOX2B
promoter; moreover, unlike PHOX2B, PHOX2A, binds also the
ATTA1 and ATTA5 sites (Fig. 2S, panel C, lanes 2–5 and 22–25),
although with lower afﬁnity.
We then asked whether the down-regulated expression of
PHOX2B was related to, and mediated by the increased expression
of PHOX2A induced by ATRA treatment. The over-expression of
PHOX2A in the SK(2)C NB cell lines showed a statistically sig-
niﬁcant 40% reduction in the expression of endogenous PHOX2B
(Fig. 4A, hatched vs black bar), thus suggesting that PHOX2A ne-
gatively modulates PHOX2B expression, although the reduction
was not as great as that observed after an ATRA challenge. These
data were conﬁrmed by silencing PHOX2A expression for 24 and
48 h (Fig. 4B, lanes 2 and 4 vs 1 and 3), and an approximately 50%
reduction in PHOX2A expression (Fig. 4C, black bars) corresponded
to a slight, but statistically signiﬁcant increase in PHOX2B ex-
pression (Fig. 4C, grey bars). In order to investigate whether the
down-regulation of PHOX2B induced by ATRA treatment was at
least partially due to an increase in PHOX2A expression, we
counteracted the ATRA-induced increase in PHOX2A expression in
SK(2)C cells transfected with PHOX2A shRNA, and measured the
corresponding level of PHOX2B mRNA. Fig. 4D (left panel) shows
that the presence of PHOX2A shRNA blocked the ATRA-induced
PHOX2A expression (grey vs hatched bars) for up to 72 h to an
extent that was not statistically different from that observed in the
samples transfected with a scrambled shRNA (shCTRL) and not
challenged to ATRA treatment (grey vs black bars). However, the
reduction in PHOX2B expression was not affected by the presence
of the PHOX2A shRNA (Fig. 4D, right panel; grey vs hatched bars) at
Fig. 3. Functional mapping of PHOX2A retinoic acid responsive elements. (A) Schematic illustration of the putative RAREs identiﬁed in the PHOX2A promoter region. Left: The
region spanning 5 Kb upstream of the PHOX2A transcriptional start site. Right: The region spanning nucleotides 10,530 to 5200 of the PHOX2A 5′-ﬂanking region. The
consensus RARE is also indicated. (B) Left: Schematic illustration of the constructs. The boxes represent the putative RARE sequences #1-#10, as assessed by means of
computer-assisted analysis (Genomatix, MatInspector), and the arrows the transcription start site. The ﬁgure shows the restriction sites used to clone the different parts of
the PHOX2A 5′-ﬂanking region; the grey oval represent the Fireﬂy luciferase reporter gene (luc). Right: Luciferase assays. SK-N-BE(2)C cells were transiently transfected with
the constructs shown on the left, and treated with ATRA for 24 h before luciferase assay. The bars show the transcriptional activity of the constructs expressed as fold-
inductions over vehicle-treated cells (mean values7SD of at least three independent experiments performed in triplicate). The asterisk indicates a statistically signiﬁcant
difference between the cells treated with ATRA or vehicle alone for the same period of time (Student's t test. *po0.05).
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regulate their own expression, but this mechanism is not involved
in regulating ATRA-induced PHOX2B down-regulation.
3.5. ATRA reduces PHOX2A protein half-life by means of proteasomal
degradation
As shown in Fig. 1A, 24 h ATRA treatment led to a substantial
and statistically signiﬁcant increase in PHOX2A expression; how-
ever, surprisingly, no trace of the protein was found after 48 h
exposure and for up to 96 h (Fig. 1A). In order to investigate
whether the delayed effects of ATRA on PHOX2A protein expres-
sion correlated with decreased protein stability, we evaluated
PHOX2A protein half-life by treating SK-N-BE(2)C cells with ATRA
or ethanol for 24 h, followed by 10 μg/ml cycloheximide for dif-
ferent time periods (Fig. 5A). The half-life of the protein was sig-
niﬁcantly reduced (50%) in comparison with the levels observed in
the cells exposed to the vehicle alone (Fig. 5A, lanes 2–5 vs lanes7–10) after no more than 90 min (Fig. 5B).
In order to conﬁrm that the effects of ATRA on protein stability
were PHOX2A speciﬁc, we studied the expression of the tran-
scription factor Sp1 after 300 min exposure to RA in the same
samples as those used in Fig. 5A: Fig. 5C shows that the presence
of RA had no effect on Sp1 expression.
In order to investigate whether the reduced stability of
PHOX2A protein was due to increased proteasome-mediated de-
gradation, SK-N-BE(2)C cells were treated with MG-132, an in-
hibitor of proteasomal activity. The cells were exposed to MG-132
for the last eight hours of a 32-h exposure period, and this in-
creased the amount of PHOX2A protein in comparison with the
amount induced by ATRA alone (Fig. 5D, lane 5 vs lane 4). The
simultaneous presence of the inhibitor for up to 24 h (a total of
48 h of ATRA treatment; Fig. 5D, lane 7), or for the last eight hours
of a 56 h exposure to ATRA (Fig. 5D, lane 9) rescued PHOX2A
protein expression from degradation (compare lanes 7 with 6 and
lanes 9 with 8). Furthermore, PHOX2A immunoprecipitation and
Fig. 4. PHOX2A induction does not mediate the ATRA-induced down-regulation of PHOX2B expression. (A) qPCR analysis of PHOX2B expression following PHOX2A over-
expression. SK-N-BE(2)C cells were transfected with PHOX2A cDNA expression vector (striped bar), and PHOX2B gene expression was determined by means of real-time PCR
using the GAPDH gene as an internal control. The bars represent the mean values7SD of three independent experiments expressed as fold-inductions in comparison with
the cells transfected with empty vector (black bar). ***po0.001 indicates statistically signiﬁcant differences in PHOX2B mRNA expression (Student's t test). (B) Western blots
of PHOX2A silencing. SK-N-BE(2)C cells were transfected with the shRNA construct targeting the 3′-UTR of PHOX2A (sh2a, lanes 2 and 4) or scrambled shRNA (shCTRL, lanes
1 and 3). PHOX2A protein levels were determined 24 (lanes 1 and 2) and 48 h after transfection (lanes 3 and 4), using an anti-PHOX2A antibody. The membrane was probed
with an antibody against β-tubulin for normalisation purposes. (C) qPCR analysis of PHOX2A (black bars) and PHOX2B expression (grey bars) upon PHOX2A silencing. SK-N-BE
(2)C cells were transfected with the shRNA construct targeting the 3′-UTR of PHOX2A (shPHOX2A) and gene expression was determined 24 and 48 h after transfection by
means of real-time PCR using the GAPDH gene as an internal control. The bars represent the mean values7SD of at least three independent experiments, expressed as fold
differences in comparison with the cells transfected with scrambled shRNA (shCTRL¼1). **po0.01 and ***po0.001 indicate statistically signiﬁcant differences in gene
expression relative to scramble transfected cells. (D) PHOX2A and PHOX2B mRNA expression upon ATRA treatment after PHOX2A silencing. SK-N-BE(2)C cells were trans-
fected with PHOX2A shRNA (shPHOX2A, grey bars) or scrambled shRNA constructs (shCTRL, striped and black bars), and treated with 10 mM ATRA (grey and striped bars) for
the indicated times. PHOX2A (left panel) and PHOX2B (right panel) gene expression was determined by means of real-time PCR using the GAPDH gene as an internal control.
The bars represent the mean values7SD of three independent experiments, expressed as relative mRNA levels calculated using the 2ΔCt method. Left panel: **po0.01 and
§§§po0.001 (one-way ANOVA, post-Tukey's test) indicate statistically signiﬁcant differences in PHOX2A mRNA expression between the cells transfected with scrambled
shRNA (striped bars) and the cells transfected with shPHOX2A (grey bars) treated with ATRA or between the cells transfected with scrambled shRNA treated with ATRA
(striped bars) or vehicle (black bars). There was no statistically signiﬁcant difference between the vehicle- and ATRA-treated cells respectively transfected with shCTRL (black
bars) and with shPHOX2A (grey bars). Right panel: ***po0.001 indicate statistically signiﬁcant differences in PHOX2B mRNA expression between the ATRA- and vehicle-
treated cells transfected with shCTRL (bars 2, 5, 8 and 11 vs 1, 4, 7 and 10) or shPHOX2A (bars 3, 6, 9 and 12 vs 1, 4, 7 and 10). There was no statistically signiﬁcant difference
between the ATRA-treated cells transfected with shPHOX2A (grey bars) and those transfected with shCTRL (striped bars).
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jugates are increased by treatment with ATRA combined with MG-
132 than treatment by ATRA alone (Fig. 5E, lane 8 vs lane 5), thus
conﬁrming that the disappearance of PHOX2A protein is due to
selective proteasomal degradation, whereas the mRNA remains
stably expressed.4. Discussion
We investigated the effects of ATRA on the expression of
PHOX2A, a candidate tumour suppressor gene [14], using the un-
differentiated SK-N-BE(2)C human NB cell line as a model, and
found that they were apparently opposite: it initially acted as a
positive regulator of gene expression, but later triggered a processthat culminated in the complete disappearance of the transcrip-
tion factor. The positive effects of ATRA were mainly due to direct
stimulation of gene transcription by means of the contribution of
three RARE sequences located in the ﬁrst 1.5 Kb of the PHOX2A
promoter, but the identity of the RA nuclear receptor isoforms
involved in this regulation is still unknown.
The increase in PHOX2A protein product during the ﬁrst 24 h of
treatment, followed by its down-regulation after 48 h even though
the expression of PHOX2A mRNA remained constantly up-regu-
lated, led us to hypothesise that ATRA might promote the dis-
appearance of PHOX2A protein by means of two different mole-
cular mechanisms: translation inhibition and/or increased protein
degradation. Our data strongly suggest that the proteasome plays a
pivotal role, and raise the question as to which pathways link
ATRA exposure to PHOX2A degradation.
Fig. 5. ATRA induces the proteasome-mediated degradation of PHOX2A protein. (A) SK-N-BE(2)C cells exposed to ethanol (lanes 1–5) or 10 μM ATRA (lanes 6–10) for 24 h
were treated with cycloheximide at a ﬁnal concentration of 10 μg/ml. The total protein extracts were obtained after treatment with cycloheximide for the indicated periods
of time, and analysed by means of Western blotting. (B) Densitometric signal quantiﬁcation expressed as the percentage of PHOX2A expression after 24 h exposure to ethanol
(triangles) or ATRA (squares). The asterisk indicates a statistically signiﬁcant difference between the control and ATRA-treated cells after 300 min (Student's t test po0.05).
C) The same protein extracts as those used in the experiment shown in panel A (lanes 1, 5, 6 and 10) were analysed for the expression of the Sp1 transcription factor by
means of Western blotting. (D) Western blots of extracts from SK-N-BE(2)C cells treated with ATRA for 24 h (lane 3), 32 h (lane 4), 48 h (lanes 6), and 56 h (lane 8), alone or in
combination with the simultaneous treatment with the proteasome inhibitors MG-132 for eight (lanes 5 and 9) and 24 h (lane 7). The positive controls were untreated SK-N-
BE(2)C cells at time 0 (lane 2), and 10 μg of nuclear extract from IMR32 cells (lane 1) E) Total extracts from SK-N-BE(2)C cells treated with EtOH (vehicle, lanes 1–3) or 105
ATRA for 24 h (lanes 4–6), followed by simultaneous treatment with MG-132 for eight hours (lanes 7–9), were immunoprecipitated with anti-PHOX2A antibodies (IP2A,
lanes 2, 5, 8), and the level of ubiquitination was evaluated by means of Western blotting using an anti-ubiquitin (Ub) antibody (upper panel). Immunoprecipitation with
chicken pre-immune IgY was used as a control, (IgY, lanes 3, 6 and 9). Lanes 1, 4 and 7 show pre-immunoprecipitation total extract [10% input (In)]. The same membranes
were stripped and re-probed with anti-PHOX2A antibody (lower panel). The asterisk indicates an speciﬁc band due to IgY heavy chain. Ub-PHOX2A: Ubiquitin-PHOX2A
conjugates.
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esis by arresting cells in the G1 phase of the cell cycle [31]. Al-
though the underlying mechanism is still unclear, it is known that
RARβ is a necessary component of the inhibitory effects of ATRA
on the growth of NB cells [42]; furthermore, RA induces cell-cycle
arrest in G1 by decreasing the cyclin-dependent kinase (Cdk) ac-
tivity required for the G1/S transition and the accumulation of the
p27Kip1Cdk inhibitor (CKI) [43,44] that impair growth and activate
the differentiation programme. The stability of p27Kip1 is regulated
by the E3 ubiquitin ligase SKP2, and RA stabilises p27Kip1 by en-
hancing the proteasome-mediated degradation of SKP2 in a
number of cancer cell lines. Like PHOX2A, SKP2 protein disappears,
but its mRNA persists during the RA treatment of SH-SY5Y cells,
thus suggesting that RA post-transcriptionally regulates SKP2 [45].
Ballas et al. and Singh et al. [46,47] have shown that REST, a key
regulator of neuronal genes during neuronal differentiation, is
regulated by ATRA in a manner that is similar to the regulation of
PHOX2A, and suggested that the degradation of REST may facil-
itate a rapid transition to terminal differentiation; given that REST
is mainly a negative regulator, this permits the differential ex-
pression of a subset of genes with lower-afﬁnity REST binding
sites. These ﬁndings suggest that regulation of proteasome-medi-
ated degradation of the proteins involved in different aspects of
cell metabolism may be a common mechanism by means of which
RA controls the order of the signalling events necessary for a cell's
response to retinoid-induced differentiation.
Like PHOX2A, PHOX2B, is overexpressed in a number of tumours
and NB cell lines. However, there are conﬂicting hypotheses con-
cerning the signiﬁcance of this in the pathogenesis of NBs. Raabeet al. [16] suggest that PHOX2B up-regulation is simply a marker of
tumour lineage and not a contributor to malignant phenotype,
given that neuroblastoma arise at a time when PHOX2B is normally
expressed during neurodevelopment, and its forced over-
expression decreases proliferation. Furthermore, they rule out
PHOX2A involvement in the pathogenesis of NBs because no
mutations have been found in the PHOX2A coding region [14,16].
As the expression of PHOX2B precedes that of PHOX2A during
development, and in vitro experiments have shown that the forced
over-expression of PHOX2B regulates PHOX2A [5,6], it is possible to
speculate that PHOX2A up-regulation may be due to a high level of
PHOX2B expression, because silencing PHOX2B in NB cell lines
leads to the down-regulation of PHOX2A [22].
However, in contrast to data described in Bachetti et al. [22],
our data suggest a new mechanism cross-regulating PHOX2A and
PHOX2B as they show that PHOX2A negatively modulates PHOX2B
expression. This discrepancy may be due to differences of cell
system (SK-N-BE(2)C cells as opposed to SH-SY5Y and IMR32 cell
lines), and so the up-regulated expression of PHOX2A and PHOX2B
in NBs might be the result of cross-regulation.
Conversely, the observation that the proliferation of un-
differentiated PHOX2Bþ neuronal progenitors promotes NB cell
proliferation and stemness indicates that PHOX2B is a critical
regulator in the pathogenesis of NBs [23]. It is not known what
decides whether PHOX2B is pro- or anti-proliferative, but it can be
hypothesised that the effects of PHOX2B over-expression depend
on cell context.
As we did not map any RARE in the PHOX2B promoter, we
wondered whether the PHOX2B down-regulation we observed
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PHOX2A, which down-regulates the expression of PHOX2B. How-
ever, by silencing endogenous PHOX2A expression, we found that
PHOX2B regulation by PHOX2A is not the mechanism underlying
the effect of RA. The association between MYCN ampliﬁcation (an
important prognostic factor in NB) and PHOX2B expression in
human NB cell lines [23], the down-regulation of MYCN expression
after an RA challenge [48,49], the up-regulation of PHOX2B asso-
ciated with MYCN over-expression, and the down-regulation of
PHOX2B and Mash1 when siRNA is used to inhibit MYCN [23], all
support the hypothesis that a high PHOX2B expression level is due
to the direct regulation of PHOX2B by MYCN, and we are currently
investigating whether the down-regulation of PHOX2B is related to
a reduction in MYCN expression.
In any case, our ﬁndings highlight the importance of the reg-
ulation of gene dosage in the processes driving ﬁnal cells differ-
entiation. The action of ATRA on PHOX2A and PHOX2B expression
may not only determine a cell's fate, but also stabilise it by
maintaining lineage-speciﬁc expression patterns, as conﬁrmed by
the observation that PHOX2B is down-regulated during ﬁnal
neuronal differentiation [13]. The dysregulation of one of these
pathways (perhaps leading to the accumulation of PHOX2Bþ
progenitor cells) may be one of the major mechanisms involved in
the pathogenesis of NBs.
The down-regulation of PHOX2B expression induced by ATRA
supports the idea that PHOX2B up-regulation is due to a block in
the differentiation process, and so its down-regulation may force
the differentiation of NB cells. Experiments aimed at identifying
drugs capable of reducing PHOX2B expression in the IMR32 cell
line [50] have not found that ATRA has any effect, and this is in line
with our unpublished ﬁndings showing that PHOX2A and PHOX2B
are not regulated by ATRA in IMR32 cells, although the cells are
ATRA responsive as measured on the basis of RARE reporter vector
activation (data not shown). However, the SH-SY5Y NB cell line
responds to ATRA in a similar manner ([33] and data not shown),
albeit with different kinetics, thus conﬁrming that the effects of
ATRA on PHOX2A and PHOX2B expression are not peculiar to the
SK-N-BE(2)C cell line but may reﬂect a general mechanism that
could be important in retinoid-induced neuronal differentiation.
These observations reinforce the idea that PHOX2A and
PHOX2B may be useful biomarkers for NB staging, prognosis and
treatment decision making [13].
These ﬁndings and other published data [51,52] shed new light
on the pathways driving undifferentiated and proliferating cells to
activate a differentiation programme by regulating the activation/
deactivation of transcription factors such as PHOX2A and PHOX2B,
which control cell-speciﬁc genes such as the DβH and cell cycle
regulators such as p27kip1. In particular, the work of Andrisani's lab.
[52] has shown that PHOX2A is intrinsically programmed to be
active for a deﬁned period of time, although in our case it is not
the activity but the presence of PHOX2A that is temporally regu-
lated by ATRA. A better understanding of the molecular mechan-
isms underlying this control may provide new opportunities for
the development of new drugs that can be used in cancer therapy.5. Conclusions
In conclusions, our ﬁndings demonstrate that PHOX2A ex-
pression is ﬁnely controlled during retinoic acid differentiation
and suggest that, together with PHOX2B down-regulation, they
may be useful biomarkers for NB staging, prognosis and treatment
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